SWOTPal for iPhoneDownload →
Home/SWOT Analysis Examples/Novo Nordisk SWOT Analysis
Novo Nordisk

Novo Nordisk SWOT Analysis

The Danish diabetes and obesity company that lost the injectable race to Eli Lilly and leads the pill race instead. Novo raised its 2026 guidance three times, from a -5% to -13% decline in adjusted sales and operating profit at constant exchange rates (February 3) to -4% to -12% (May 6), 0% to -6% (August 4) and -2% to +2% (November 4). Q3 2026 adjusted sales were DKK 79.2B, up 4% at CER against a DKK 73.6B FactSet consensus, and adjusted operating profit rose 27%. The Wegovy pill, launched in the US on January 5, 2026, sold DKK 2.3B, 3.2B and 5.4B in the first three quarters, has more than 8 million cumulative US prescriptions, and on Lilly's own count takes about 6 in 10 US oral obesity starts against Foundayo. The injectables are shrinking: Ozempic -5% and Wegovy injection -2% in Q3, semaglutide generics in Canada and India, and a $675 US list price from January 1, 2027. This SWOT centers on the 'Two-Market Split': Lilly leads injectables (Mounjaro plus Zepbound $16.07B in Q3, about 63% of the US incretin market), Novo leads pills (6.8% of its Q3 sales vs 0.75% of Lilly's, our calculation), which is why both raised guidance in the same quarter. CagriSema's FDA decision is expected around the turn of 2026-27, and the shares are about 74% below their June 2024 peak.

PharmaceuticalsLast edited 2026-11-09
⌗ TOWS Matrix
DEEP DIVERead full analysis: Novo Nordisk SWOT Analysis 2026: The Pill LeadRead →
★ Key Takeaways
  • 1Top strength — The Leading GLP-1 Pill: The Wegovy pill sold DKK 2.3 billion in Q1 2026, DKK 3.2 billion in Q2 and DKK 5.4 billion in Q3…
  • 2Top weakness — The Injectables Are Shrinking: Ozempic fell 5% to DKK 29.7 billion and Wegovy injection 2% to DKK 20.4 billion in Q3…
  • 3Biggest opportunity — CagriSema in 2027: Novo filed CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with the FDA in December 2025; the…

Novo Nordisk SWOT Snapshot

CategoryTop factors
Strengths
  • The Leading GLP-1 Pill: The Wegovy pill sold DKK 2.3 billion in Q1 2026, DKK 3.2 billion…
  • First to the Prescriber: Launched three months before Lilly's Foundayo (approved April 1…
  • Guidance Raised Three Times: The 2026 guide for adjusted sales and operating profit at…
Weaknesses
  • The Injectables Are Shrinking: Ozempic fell 5% to DKK 29.7 billion and Wegovy injection 2%…
  • The Pill Is Still Small: The Wegovy pill was 6.8% of Q3 2026 sales (our calculation), so…
  • The Head-to-Head Loss: In REDEFINE 4, CagriSema produced a 23% body-weight reduction…
Opportunities
  • CagriSema in 2027: Novo filed CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with…
  • Medicare Coverage: A Medicare GLP-1 Bridge pilot has covered obesity treatment since July…
  • Branded Telehealth Distribution: Since a March 9, 2026 agreement that ended Novo's…
Threats
  • Semaglutide Generics Abroad: The compound patent expired in India, China and Brazil in…
  • The January 2027 List-Price Cut: Under the November 2025 agreement with the US…
  • Lilly in Injectables: Lilly holds about 63% of the US incretin market, grew Mounjaro 65%…

The SWOT

every quadrant, every point ↘

Novo Nordisk Strengths (2026)

6
The Leading GLP-1 Pill: The Wegovy pill sold DKK 2.3 billion in Q1 2026, DKK 3.2 billion in Q2 and DKK 5.4 billion in Q3 (US DKK 4.2 billion), with more than 8 million cumulative US prescriptions since its January 5, 2026 launch, about 3.6 million of them in Q3.
First to the Prescriber: Launched three months before Lilly's Foundayo (approved April 1, 2026), the Wegovy pill takes about 6 in 10 US oral obesity starts on Lilly's own Q3 count, and sold roughly $0.8 billion in Q3 against Foundayo's $184 million (at about 6.5 kroner per dollar, our calculation).
Guidance Raised Three Times: The 2026 guide for adjusted sales and operating profit at constant exchange rates moved from -5% to -13% (February) to -2% to +2% (November), and Q3 adjusted sales of DKK 79.2 billion beat the DKK 73.6 billion FactSet consensus by more than DKK 5 billion.
A Cost Reset That Shows in Profit: Q3 2026 adjusted operating profit rose 27% at CER to DKK 31.7 billion on 4% sales growth; the 2025 transformation cut full-time staff 10% to 68,794, and the free-cash-flow guide was raised to DKK 60-70 billion from DKK 45-55 billion.
International Operations Still Growing: International Operations grew 8% at CER through the first nine months of 2026, and Wegovy (injection and pill) grew 31% outside the US in Q3.
Diabetes Scale: Diabetes was 67% of FY2025 sales (DKK 309.1 billion, +10% CER) and obesity 26.6% (our calculation), and Novo held a 42.7% volume share of the global insulin market and 30.1% of the diabetes care market by value at November 2025.

Novo Nordisk Weaknesses (2026)

6
The Injectables Are Shrinking: Ozempic fell 5% to DKK 29.7 billion and Wegovy injection 2% to DKK 20.4 billion in Q3 2026, and US Wegovy injection sales fell 15% over nine months on lower realized prices.
The Pill Is Still Small: The Wegovy pill was 6.8% of Q3 2026 sales (our calculation), so its growth has to outrun a DKK 50.1 billion quarterly injectable business that is declining.
The Head-to-Head Loss: In REDEFINE 4, CagriSema produced a 23% body-weight reduction against 25.5% for Lilly's tirzepatide over 84 weeks, and Copenhagen shares fell 16.5% on February 23, 2026; Novo's next injectable cannot be sold as the efficacy leader.
Pipeline Write-Downs: Novo impaired DKK 4.0 billion for monlunabant in Q2 2026 and DKK 4.6 billion for ziltivekimab in Q3, plus DKK 4.1 billion to shrink its manufacturing network, so reported Q3 operating profit fell 9% while adjusted profit rose 27%.
A Stock That Has Not Recovered: Shares fell from DKK 1,028 on June 25, 2024 to DKK 269 on November 6, 2026, about 74% (our calculation); the August guide raise closed 4.3% lower and the September 21 Capital Markets Day 7.7% lower.
Finance Leadership Change: CFO Karsten Munk Knudsen leaves at the end of 2026 and will be succeeded by Luigi La Corte, currently CFO of Galderma, just as the January 2027 US list-price cut takes effect.

Novo Nordisk Opportunities (2026)

6
CagriSema in 2027: Novo filed CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with the FDA in December 2025; the decision is expected around the turn of 2026-27 and Novo is preparing a US launch in early 2027, subject to approval.
Medicare Coverage: A Medicare GLP-1 Bridge pilot has covered obesity treatment since July 1, 2026, a reimbursed population that both the pill and the injectables can serve.
Branded Telehealth Distribution: Since a March 9, 2026 agreement that ended Novo's lawsuit, Hims & Hers sells branded Wegovy at cash prices and stops marketing compounded copies, with a carve-out for 'clinically necessary' compounding.
More Pill Markets and Formats: The Wegovy pill is sold in 8 markets at US self-pay prices of $149 to $299 a month by dose, ships without a cold chain, and the Ozempic pill followed in the US on May 4, 2026.
MASH Through Akero: Novo closed the Akero acquisition on December 9, 2025 for $54 a share in cash (about $4.7 billion) plus a $6 contingent value right tied to efruxifermin's approval in MASH cirrhosis, a liver-disease asset outside GLP-1.
A Rebuilt Pipeline Target: The September 21, 2026 Capital Markets Day set a goal of more than five multi-blockbusters by 2030, giving investors a public scorecard for the post-semaglutide pipeline.

Novo Nordisk Threats (2026)

6
Semaglutide Generics Abroad: The compound patent expired in India, China and Brazil in March 2026 and the Canadian patent lapsed over unpaid maintenance fees; generics have launched in India and Canada, and Novo's Q3 report cites the Canadian loss of exclusivity as a drag on Ozempic. US, European and Japanese exclusivity runs into the early 2030s.
The January 2027 List-Price Cut: Under the November 2025 agreement with the US administration, the US list price of Wegovy and Ozempic falls to $675 a month on January 1, 2027, about 50% and 35% below current list; Q1 2027 is the first quarter at that price.
Lilly in Injectables: Lilly holds about 63% of the US incretin market, grew Mounjaro 65% and Zepbound 49% in Q3 2026, and plans a retatrutide filing in Q1 2027.
Foundayo's Broader Rollout: Lilly's pill has launched in the UAE, UK, Saudi Arabia and Mexico and is under review in more than 40 more countries, so Novo's roughly 6-in-10 share of US oral starts will be tested as Foundayo scales.
Amgen and Later Entrants: Amgen's MariTide reports Phase 3 data (MARITIME-1 and -2) in 2027 after about 20% weight loss at 52 weeks in Phase 2, a 2027-28 threat rather than a 2026 one.
Coverage Pullbacks: Novo's Q3 2026 report cites reduced Medicaid obesity coverage as a headwind, on top of lower US realized prices for Wegovy injection.

TOWS Strategy Matrix

PREMIUM

From insight to action — pairing the four quadrants into concrete strategies.

SOGrowthStrengths × Opportunities
Press the Pill Lead Before Foundayo Scales: Use the roughly 6-in-10 share of US oral starts (Strength) to add pill markets beyond the current 8 (Opportunity) ahead of Lilly's 40-country review pipeline.
Pair Pill Volume With Medicare: Use the leading pill (Strength) to capture patients under the Medicare GLP-1 Bridge (Opportunity), with the $149-299 self-pay ladder outside it.
Show 3 more ↓
Fund CagriSema's Launch From the Cost Reset: Use a 27% rise in Q3 adjusted operating profit and a DKK 60-70 billion free-cash-flow guide (Strength) to back the early-2027 CagriSema launch (Opportunity).
Route Branded Demand Through Telehealth: Use the pill's prescription momentum (Strength) with the Hims & Hers branded-Wegovy agreement (Opportunity) to pull cash-pay patients away from compounded copies.
Diversify From Diabetes Scale: Use diabetes scale and 8% International Operations growth (Strength) to commercialize Akero's efruxifermin in MASH (Opportunity) outside the GLP-1 price fight.
WOTurnaroundWeaknesses × Opportunities
Grow the Pill Faster Than the Injectables Shrink: Offset Ozempic -5% and Wegovy injection -2% (Weakness) with Wegovy pill sales above DKK 6.5 billion in Q4 2026 and new pill markets (Opportunity).
Reposition CagriSema Without the Efficacy Lead: Address the REDEFINE 4 loss (Weakness) by selling CagriSema to payers as a second approved combination (Opportunity) rather than as the strongest molecule.
Show 3 more ↓
Rebuild Pipeline Credibility: Answer DKK 8.6 billion of Q2-Q3 write-downs (Weakness) by reporting progress against the more-than-five multi-blockbusters target (Opportunity) every quarter.
Recover US Injectable Volume Through Medicare: Address US Wegovy injection sales down 15% over nine months on lower realized prices (Weakness) by adding Medicare Bridge patients (Opportunity) to offset price with volume.
Show Investors the Pill Business: Address a share price about 74% below its peak (Weakness) by disclosing pill prescriptions and share as Medicare and telehealth volume builds (Opportunity).
STDefenseStrengths × Threats
Shift the Base Before the Price Cut: Use pill growth (Strength) to lower reliance on injectables before the $675 US list price arrives on January 1, 2027 (Threat).
Hold Oral Share Against Foundayo: Use first-mover position and 8 million+ prescriptions (Strength) to keep at least half of US oral obesity starts as Foundayo rolls out (Threat).
Show 3 more ↓
Ship Pills Where Compound Patents Lapsed: Use the oral formulation, which Novo is defending through patent suits against Indian generic makers (Strength), to keep a protected product in markets where semaglutide generics have launched (Threat).
Compete on Cost Where Generics Arrive: Use the 2025 cost reset (Strength) to defend Ozempic in Canada and India against generics (Threat) without giving up the margin gains.
Hold Diabetes Prescribers: Use a 42.7% insulin volume share and 30.1% diabetes value share (Strength) to keep diabetes prescribers as Lilly's injectable share grows (Threat).
WTRetreatWeaknesses × Threats
Plan for Q1 2027 as the Stress Quarter: Given shrinking injectables (Weakness) and the $675 list price (Threat), set the 2027 plan on combined Ozempic and Wegovy injection sales falling less than 10% at CER.
Do Not Bet the Company on CagriSema: Given the head-to-head loss (Weakness) and Lilly's retatrutide filing in Q1 2027 (Threat), keep the pill, not CagriSema, as the base case.
Show 3 more ↓
Prioritize Fewer, Higher-Probability Programs: Given DKK 8.6 billion of impairments (Weakness) and later entrants such as MariTide (Threat), concentrate R&D where the evidence is strongest.
Guide to What the Pill Can Carry: Given a stock that has not rewarded three raises (Weakness) and the generic-plus-list-price squeeze (Threat), set a February 2027 guide that is not below the 2026 range of -2% to +2% only if the pill trajectory supports it.
Defend Coverage With Volume: Given reduced Medicaid obesity coverage (Threat) and falling US realized prices (Weakness), push volume through Medicare and branded cash-pay channels rather than deeper discounting.
make it yours ↘

Want to customize this analysis?

Tailor this Novo Nordisk SWOT to your specific context — your market, your goals, your strategy.

SISTER SITE · FRAMEWORKLIST.COM

Beyond SWOT: other frameworks to try

SWOT is one of 100+ thinking frameworks on FrameworkList — covering strategy, prioritization, risk, business models, and decision-making.

Porter's Five ForcesPESTELPre-mortemRICE ScoringLean CanvasOKR
Browse all 100+ frameworks on FrameworkList →

Frequently Asked Questions

What are the Strengths of Novo Nordisk in their SWOT analysis?

+
  • The Leading GLP-1 Pill: The Wegovy pill sold DKK 2.3 billion in Q1 2026, DKK 3.2 billion in Q2 and DKK 5.4 billion in Q3 (US DKK 4.2 billion), with more than 8 million cumulative US prescriptions since its January 5, 2026 launch, about 3.6 million of them in Q3.
  • First to the Prescriber: Launched three months before Lilly's Foundayo (approved April 1, 2026), the Wegovy pill takes about 6 in 10 US oral obesity starts on Lilly's own Q3 count, and sold roughly $0.8 billion in Q3 against Foundayo's $184 million (at about 6.5 kroner per dollar, our calculation).
  • Guidance Raised Three Times: The 2026 guide for adjusted sales and operating profit at constant exchange rates moved from -5% to -13% (February) to -2% to +2% (November), and Q3 adjusted sales of DKK 79.2 billion beat the DKK 73.6 billion FactSet consensus by more than DKK 5 billion.
  • A Cost Reset That Shows in Profit: Q3 2026 adjusted operating profit rose 27% at CER to DKK 31.7 billion on 4% sales growth; the 2025 transformation cut full-time staff 10% to 68,794, and the free-cash-flow guide was raised to DKK 60-70 billion from DKK 45-55 billion.
  • International Operations Still Growing: International Operations grew 8% at CER through the first nine months of 2026, and Wegovy (injection and pill) grew 31% outside the US in Q3.
  • Diabetes Scale: Diabetes was 67% of FY2025 sales (DKK 309.1 billion, +10% CER) and obesity 26.6% (our calculation), and Novo held a 42.7% volume share of the global insulin market and 30.1% of the diabetes care market by value at November 2025.

What are the Weaknesses of Novo Nordisk in their SWOT analysis?

+
  • The Injectables Are Shrinking: Ozempic fell 5% to DKK 29.7 billion and Wegovy injection 2% to DKK 20.4 billion in Q3 2026, and US Wegovy injection sales fell 15% over nine months on lower realized prices.
  • The Pill Is Still Small: The Wegovy pill was 6.8% of Q3 2026 sales (our calculation), so its growth has to outrun a DKK 50.1 billion quarterly injectable business that is declining.
  • The Head-to-Head Loss: In REDEFINE 4, CagriSema produced a 23% body-weight reduction against 25.5% for Lilly's tirzepatide over 84 weeks, and Copenhagen shares fell 16.5% on February 23, 2026; Novo's next injectable cannot be sold as the efficacy leader.
  • Pipeline Write-Downs: Novo impaired DKK 4.0 billion for monlunabant in Q2 2026 and DKK 4.6 billion for ziltivekimab in Q3, plus DKK 4.1 billion to shrink its manufacturing network, so reported Q3 operating profit fell 9% while adjusted profit rose 27%.
  • A Stock That Has Not Recovered: Shares fell from DKK 1,028 on June 25, 2024 to DKK 269 on November 6, 2026, about 74% (our calculation); the August guide raise closed 4.3% lower and the September 21 Capital Markets Day 7.7% lower.
  • Finance Leadership Change: CFO Karsten Munk Knudsen leaves at the end of 2026 and will be succeeded by Luigi La Corte, currently CFO of Galderma, just as the January 2027 US list-price cut takes effect.

What are the Opportunities of Novo Nordisk in their SWOT analysis?

+
  • CagriSema in 2027: Novo filed CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with the FDA in December 2025; the decision is expected around the turn of 2026-27 and Novo is preparing a US launch in early 2027, subject to approval.
  • Medicare Coverage: A Medicare GLP-1 Bridge pilot has covered obesity treatment since July 1, 2026, a reimbursed population that both the pill and the injectables can serve.
  • Branded Telehealth Distribution: Since a March 9, 2026 agreement that ended Novo's lawsuit, Hims & Hers sells branded Wegovy at cash prices and stops marketing compounded copies, with a carve-out for 'clinically necessary' compounding.
  • More Pill Markets and Formats: The Wegovy pill is sold in 8 markets at US self-pay prices of $149 to $299 a month by dose, ships without a cold chain, and the Ozempic pill followed in the US on May 4, 2026.
  • MASH Through Akero: Novo closed the Akero acquisition on December 9, 2025 for $54 a share in cash (about $4.7 billion) plus a $6 contingent value right tied to efruxifermin's approval in MASH cirrhosis, a liver-disease asset outside GLP-1.
  • A Rebuilt Pipeline Target: The September 21, 2026 Capital Markets Day set a goal of more than five multi-blockbusters by 2030, giving investors a public scorecard for the post-semaglutide pipeline.

What are the Threats of Novo Nordisk in their SWOT analysis?

+
  • Semaglutide Generics Abroad: The compound patent expired in India, China and Brazil in March 2026 and the Canadian patent lapsed over unpaid maintenance fees; generics have launched in India and Canada, and Novo's Q3 report cites the Canadian loss of exclusivity as a drag on Ozempic. US, European and Japanese exclusivity runs into the early 2030s.
  • The January 2027 List-Price Cut: Under the November 2025 agreement with the US administration, the US list price of Wegovy and Ozempic falls to $675 a month on January 1, 2027, about 50% and 35% below current list; Q1 2027 is the first quarter at that price.
  • Lilly in Injectables: Lilly holds about 63% of the US incretin market, grew Mounjaro 65% and Zepbound 49% in Q3 2026, and plans a retatrutide filing in Q1 2027.
  • Foundayo's Broader Rollout: Lilly's pill has launched in the UAE, UK, Saudi Arabia and Mexico and is under review in more than 40 more countries, so Novo's roughly 6-in-10 share of US oral starts will be tested as Foundayo scales.
  • Amgen and Later Entrants: Amgen's MariTide reports Phase 3 data (MARITIME-1 and -2) in 2027 after about 20% weight loss at 52 weeks in Phase 2, a 2027-28 threat rather than a 2026 one.
  • Coverage Pullbacks: Novo's Q3 2026 report cites reduced Medicaid obesity coverage as a headwind, on top of lower US realized prices for Wegovy injection.

More Examples

★ AI AGENT

Analyze any company in 30 seconds

Free to start · No credit card · Your SWOT in under a minute.

Analyze Free →